- Developmental dyspraxia, or developmental coordination disorder (DCD), is a neurological condition affecting motor coordination and cognitive processing in children. Pharmacologic treatment is typically used alongside occupational and speech therapy
- The market is growing due to increasing diagnosis rates, improvements in school-based screening, and availability of combination drug therapy
- North America dominates the developmental dyspraxia drug market with an estimated share of 43.6%, driven by well-established pediatric neurology networks, widespread implementation of early diagnosis programs, and robust pharmaceutical research and development (R&D) capabilities
- The Asia-Pacific region is projected to witness the highest compound annual growth rate (CAGR) of 6.2% in the developmental dyspraxia drug market, fueled by rising investments in pediatric health services and increased awareness about neurodevelopmental disorders
- The stimulants segment is projected to dominate the market with the largest share of 39.7%, owing to their established role in improving attention span and executive function in children
